Screener Summaries Updates Institutions Sign In More Updates › Other Events › INMB Other Events · Jun 23, 2026
Inmune Bio, Inc. received official meeting minutes from a pre-Marketing Authorization Application (pre-MAA) Scientific… INMB Inmune Bio, Inc.
Inmune Bio, Inc. received official meeting minutes from a pre-Marketing Authorization Application (pre-MAA) Scientific Advice meeting with the UK Medicines & Healthcare products Regulatory Agency (MHRA) regarding CORDStrom (Ebstrocel) for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). Inmune Bio, Inc. is a biotechnology company focused on developing and commercializing immune-modulating products.
More from Inmune Bio, Inc. INmune Bio prices $4.5M registered direct offering at $1.50 per share with concurrent private placement of warrants Oct 29, 2026 INmune Bio submits UK pre-MAA for Ebstrocel and partners with Uniphar for international access Oct 21, 2026 INmune Bio, Inc. appointed R. Duane Clark II and James Sapirstein as independent directors on September 8, 2026… Sep 14, 2026 INmune Bio Inc. announced the receipt of approximately $4.2 million in research and development cash rebates from… Jul 31, 2026 On June 30, 2026, INmune Bio, Inc. entered into a warrant inducement offer letter and an amendment to common stock… Jul 1, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
